Posted BY: Jasmine | NwoReport
Over the past 18 months, skeptics of mRNA Covid-19 vaccines and those pointing out high rates of adverse reactions have been subject to ostracism, de-platforming, and flawed ‘fact checks‘ to shut down opinions and analyses which conflicted with official narratives.
Now, the data has begun to speak for itself, thanks to people like former Blackrock portfolio manager Ed Dowd, who has devoted the last several years to deep-dive research and analysis of pandemic-related data (in fact, he’s written an excellent book on the topic). Dowd, along with partners Carlos Alegria and Yuri Nunes, launched Phinance Technologies – where, aside from traditional macroeconomic analysis, they have produced comprehensive reports on pandemic-related disabilities and excess deaths using official data.
Trending: McCarthy gives Tucker Carlson access to a trove of Jan. 6 riot tape
Their latest analysis reveals that the rate of Serious Adverse Events in the mRNA Covid-19 vaccine clinical trials closely tracks a spike in disabilities reported after the vaccine rollout.
Via Phinance Technologies (emphasis ours),
In part 3 of our US disabilities analysis, we observed that the rise in disability rates post-2/2021 correlates closely with the rollout of the vaccination schedule. When looking at changes in disabilities on a wider time frame (since 2008) we observe that the disability rates rose or fell from month to month but tended to be relatively stable over time. However, as shown in part 1, the change in behavior since early 2021 is clearly an abnormal occurrence with a high level of statistical significance. It happens to be highly correlated to the cumulative Covid-19 vaccine rollout, but we cannot state that the correlation is statistically meaningful as it is based on a cumulative plot with obvious autocorrelation.
In this section, we provide further evidence that the most likely cause of the rise in disabilities is the Covid-19 vaccines. For that purpose, we model the expected rise in disabilities due to the vaccination rollout in the general population. We do so by using the rates of Serious Adverse Events (SAEs) obtained by the safety analysis of the mRNA vaccine (Pfizer and Moderna) clinical trials, performed in the Vaccine journal paper we reviewed here, and our analysis in part five.